NLEM (India) vs. WHO Model List of Essential Medicines
Compares India's National List of Essential Medicines (NLEM) with the WHO's global model list, highlighting similarities, differences, and India-specific considerations.
NLEM (India) vs. WHO Model List of Essential Medicines
Feature
National List of Essential Medicines (NLEM), India
WHO Model List of Essential Medicines
Objective
Ensure availability, affordability, and accessibility of priority medicines for India's health needs.
Provide guidance to countries for developing their own national lists based on public health priorities.
Scope
Tailored to India's disease burden, economic conditions, and healthcare infrastructure.
Global benchmark, adaptable by countries.
Selection Criteria
Public health impact, proven efficacy & safety, affordability, availability.
Similar criteria, focusing on public health impact and evidence-based medicine.
Number of Drugs
Dynamic; latest 2022 list has 384 drugs.
Dynamic; latest list (2023) has 500+ medicines and vaccines.
Price Control
Directly influences price ceiling mechanisms via NPPA.
Does not directly mandate price controls but influences procurement and policy.
Policy Tool
Guides government procurement, pricing, and public health programs (e.g., Ayushman Bharat).
Serves as a reference for national policy formulation.
Recent Updates
NLEM 2022 included COVID-19 drugs, certain cancer drugs.
WHO list updated periodically to reflect new scientific evidence and health priorities.
NLEM (India) vs. WHO Model List of Essential Medicines
Compares India's National List of Essential Medicines (NLEM) with the WHO's global model list, highlighting similarities, differences, and India-specific considerations.
NLEM (India) vs. WHO Model List of Essential Medicines
Feature
National List of Essential Medicines (NLEM), India
WHO Model List of Essential Medicines
Objective
Ensure availability, affordability, and accessibility of priority medicines for India's health needs.
Provide guidance to countries for developing their own national lists based on public health priorities.
Scope
Tailored to India's disease burden, economic conditions, and healthcare infrastructure.
Global benchmark, adaptable by countries.
Selection Criteria
Public health impact, proven efficacy & safety, affordability, availability.
Similar criteria, focusing on public health impact and evidence-based medicine.
Number of Drugs
Dynamic; latest 2022 list has 384 drugs.
Dynamic; latest list (2023) has 500+ medicines and vaccines.
Price Control
Directly influences price ceiling mechanisms via NPPA.
Does not directly mandate price controls but influences procurement and policy.
Policy Tool
Guides government procurement, pricing, and public health programs (e.g., Ayushman Bharat).
Serves as a reference for national policy formulation.
Recent Updates
NLEM 2022 included COVID-19 drugs, certain cancer drugs.
WHO list updated periodically to reflect new scientific evidence and health priorities.
The National List of Essential Medicines (NLEM) is a curated list of medicines that are considered most important for a country's health system. It identifies drugs that should be available at all times, in adequate quantities, and in appropriate dosage forms, at affordable prices, to meet the priority health needs of the population. The core idea is to ensure that basic healthcare is accessible to everyone, preventing situations where life-saving or critical treatments are unavailable due to cost or supply issues. It acts as a guide for government procurement, pricing policies, and public health programs, ensuring that resources are focused on the most impactful and necessary medications. The NLEM is dynamic, reviewed periodically to incorporate new scientific evidence and evolving health priorities.
Historical Background
The concept of essential medicines isn't new; the World Health Organization (WHO) first published its Model List of Essential Medicines in 1977 to help countries develop their own lists. India adopted this principle, and the first National List of Essential Medicines was released in 1996. The primary driver was the recognition that many life-saving drugs were either unavailable or prohibitively expensive for a large segment of the Indian population. The goal was to create a framework that would ensure availability and affordability of critical medicines, thereby strengthening the public health system. Subsequent revisions have occurred periodically, with significant updates in 2003, 2011, 2015, and most recently in 2022. Each revision aims to update the list based on current disease prevalence, new drug discoveries, and changes in treatment protocols, while also considering affordability and accessibility. The process involves extensive consultation with experts, medical professionals, and stakeholders.
Key Points
15 points
1.
The National List of Essential Medicines (NLEM) is a dynamic list, meaning it's not static. It gets reviewed and updated periodically, typically every few years. The latest list, released in 2022, contains 384 drugs across 27 therapeutic categories. This ensures the list remains relevant to current health needs and scientific advancements, unlike a fixed list that would quickly become outdated.
2.
The selection criteria for inclusion in the NLEM are rigorous. Drugs are chosen based on their public health impact, proven efficacy and safety, affordability, and availability. This means not every new drug or expensive treatment makes it onto the list; it prioritizes what's most crucial for the majority of the population.
3.
A key objective of the NLEM is to promote the use of generic medicines. By including specific drugs, the government encourages their production and prescription in their generic forms, which are significantly cheaper than branded versions. This directly addresses the affordability challenge for patients.
Visual Insights
NLEM (India) vs. WHO Model List of Essential Medicines
Compares India's National List of Essential Medicines (NLEM) with the WHO's global model list, highlighting similarities, differences, and India-specific considerations.
Feature
National List of Essential Medicines (NLEM), India
WHO Model List of Essential Medicines
Objective
Ensure availability, affordability, and accessibility of priority medicines for India's health needs.
Provide guidance to countries for developing their own national lists based on public health priorities.
Scope
Tailored to India's disease burden, economic conditions, and healthcare infrastructure.
Global benchmark, adaptable by countries.
Selection Criteria
Public health impact, proven efficacy & safety, affordability, availability.
Similar criteria, focusing on public health impact and evidence-based medicine.
Number of Drugs
Dynamic; latest 2022 list has 384 drugs.
Dynamic; latest list (2023) has 500+ medicines and vaccines.
Price Control
Directly influences price ceiling mechanisms via NPPA.
Recent Real-World Examples
1 examples
Illustrated in 1 real-world examples from Apr 2026 to Apr 2026
The National List of Essential Medicines (NLEM) is a crucial concept for the UPSC Civil Services Exam, particularly for the General Studies papers. In GS-II (Governance and Social Justice), it directly relates to public health policies, healthcare access, and government initiatives. In GS-III (Economy and Environment), its connection to the pharmaceutical industry, price control mechanisms, and economic aspects of healthcare makes it relevant. For the Essay paper, it can be a strong point to discuss healthcare affordability and government responsibility. Examiners test the NLEM by asking about its purpose, its impact on drug pricing, its role in ensuring equitable healthcare, and its relationship with bodies like the NPPA. Recent revisions, like the 2022 list, are often a focal point. Students should be prepared to discuss its challenges, such as ensuring availability and promoting generics, and its role in schemes like Ayushman Bharat. Understanding the 'why' behind the list – to make critical medicines accessible and affordable – is key to answering questions effectively.
❓
Frequently Asked Questions
6
1. What is the most common MCQ trap related to the National List of Essential Medicines (NLEM) and its numbers?
The most common trap involves confusing the total number of drugs or therapeutic categories with the numbers from previous lists or the WHO's model list. For instance, students might incorrectly recall the 2022 NLEM having 384 drugs or 27 categories, or confuse it with the WHO's list size.
Exam Tip
Memorize the current numbers (384 drugs, 27 categories for 2022 NLEM) and specifically note that the list is dynamic and updated periodically. Always check the year of the NLEM being referenced in the question.
2. Why does the National List of Essential Medicines (NLEM) exist — what critical problem does it solve that other policies don't?
The NLEM exists to ensure that essential, life-saving, and high-priority medicines are available and affordable to all citizens, preventing market failures where critical drugs are either unavailable or too expensive for the majority.
•Addresses market failures: Pharmaceutical markets often prioritize profitable drugs over essential ones. NLEM corrects this by identifying and promoting essential medicines.
Political Concept
National List of Essential Medicines
What is National List of Essential Medicines?
The National List of Essential Medicines (NLEM) is a curated list of medicines that are considered most important for a country's health system. It identifies drugs that should be available at all times, in adequate quantities, and in appropriate dosage forms, at affordable prices, to meet the priority health needs of the population. The core idea is to ensure that basic healthcare is accessible to everyone, preventing situations where life-saving or critical treatments are unavailable due to cost or supply issues. It acts as a guide for government procurement, pricing policies, and public health programs, ensuring that resources are focused on the most impactful and necessary medications. The NLEM is dynamic, reviewed periodically to incorporate new scientific evidence and evolving health priorities.
Historical Background
The concept of essential medicines isn't new; the World Health Organization (WHO) first published its Model List of Essential Medicines in 1977 to help countries develop their own lists. India adopted this principle, and the first National List of Essential Medicines was released in 1996. The primary driver was the recognition that many life-saving drugs were either unavailable or prohibitively expensive for a large segment of the Indian population. The goal was to create a framework that would ensure availability and affordability of critical medicines, thereby strengthening the public health system. Subsequent revisions have occurred periodically, with significant updates in 2003, 2011, 2015, and most recently in 2022. Each revision aims to update the list based on current disease prevalence, new drug discoveries, and changes in treatment protocols, while also considering affordability and accessibility. The process involves extensive consultation with experts, medical professionals, and stakeholders.
Key Points
15 points
1.
The National List of Essential Medicines (NLEM) is a dynamic list, meaning it's not static. It gets reviewed and updated periodically, typically every few years. The latest list, released in 2022, contains 384 drugs across 27 therapeutic categories. This ensures the list remains relevant to current health needs and scientific advancements, unlike a fixed list that would quickly become outdated.
2.
The selection criteria for inclusion in the NLEM are rigorous. Drugs are chosen based on their public health impact, proven efficacy and safety, affordability, and availability. This means not every new drug or expensive treatment makes it onto the list; it prioritizes what's most crucial for the majority of the population.
3.
A key objective of the NLEM is to promote the use of generic medicines. By including specific drugs, the government encourages their production and prescription in their generic forms, which are significantly cheaper than branded versions. This directly addresses the affordability challenge for patients.
Visual Insights
NLEM (India) vs. WHO Model List of Essential Medicines
Compares India's National List of Essential Medicines (NLEM) with the WHO's global model list, highlighting similarities, differences, and India-specific considerations.
Feature
National List of Essential Medicines (NLEM), India
WHO Model List of Essential Medicines
Objective
Ensure availability, affordability, and accessibility of priority medicines for India's health needs.
Provide guidance to countries for developing their own national lists based on public health priorities.
Scope
Tailored to India's disease burden, economic conditions, and healthcare infrastructure.
Global benchmark, adaptable by countries.
Selection Criteria
Public health impact, proven efficacy & safety, affordability, availability.
Similar criteria, focusing on public health impact and evidence-based medicine.
Number of Drugs
Dynamic; latest 2022 list has 384 drugs.
Dynamic; latest list (2023) has 500+ medicines and vaccines.
Price Control
Directly influences price ceiling mechanisms via NPPA.
Recent Real-World Examples
1 examples
Illustrated in 1 real-world examples from Apr 2026 to Apr 2026
The National List of Essential Medicines (NLEM) is a crucial concept for the UPSC Civil Services Exam, particularly for the General Studies papers. In GS-II (Governance and Social Justice), it directly relates to public health policies, healthcare access, and government initiatives. In GS-III (Economy and Environment), its connection to the pharmaceutical industry, price control mechanisms, and economic aspects of healthcare makes it relevant. For the Essay paper, it can be a strong point to discuss healthcare affordability and government responsibility. Examiners test the NLEM by asking about its purpose, its impact on drug pricing, its role in ensuring equitable healthcare, and its relationship with bodies like the NPPA. Recent revisions, like the 2022 list, are often a focal point. Students should be prepared to discuss its challenges, such as ensuring availability and promoting generics, and its role in schemes like Ayushman Bharat. Understanding the 'why' behind the list – to make critical medicines accessible and affordable – is key to answering questions effectively.
❓
Frequently Asked Questions
6
1. What is the most common MCQ trap related to the National List of Essential Medicines (NLEM) and its numbers?
The most common trap involves confusing the total number of drugs or therapeutic categories with the numbers from previous lists or the WHO's model list. For instance, students might incorrectly recall the 2022 NLEM having 384 drugs or 27 categories, or confuse it with the WHO's list size.
Exam Tip
Memorize the current numbers (384 drugs, 27 categories for 2022 NLEM) and specifically note that the list is dynamic and updated periodically. Always check the year of the NLEM being referenced in the question.
2. Why does the National List of Essential Medicines (NLEM) exist — what critical problem does it solve that other policies don't?
The NLEM exists to ensure that essential, life-saving, and high-priority medicines are available and affordable to all citizens, preventing market failures where critical drugs are either unavailable or too expensive for the majority.
•Addresses market failures: Pharmaceutical markets often prioritize profitable drugs over essential ones. NLEM corrects this by identifying and promoting essential medicines.
4.
The NLEM guides the government's price control mechanisms. Drugs listed in the NLEM are subject to price ceilings set by the National Pharmaceutical Pricing Authority (NPPA). This is a critical tool to ensure that essential medicines remain affordable for the common person, as seen with the ongoing debates around drug pricing.
5.
The NLEM is not just a list; it's a policy tool. It influences government procurement decisions, helping public health facilities stock essential medicines. It also guides state governments in formulating their own lists and procurement strategies, ensuring a more coordinated approach to drug availability across the country.
6.
The NLEM is divided into categories based on therapeutic areas, such as cardiovascular drugs, anti-infectives, and pain management. This categorization helps in organizing the list and ensures that a wide range of health conditions are covered.
7.
A major challenge is ensuring the availability of NLEM drugs. Inclusion on the list doesn't automatically guarantee supply. The government needs robust supply chain management and monitoring mechanisms to ensure that these medicines are actually available in public health facilities and pharmacies, especially in remote areas.
8.
The 2022 NLEM revision saw the inclusion of new drugs and the exclusion of others. For instance, it included drugs for conditions like COVID-19 and certain cancers, reflecting evolving health priorities. Conversely, drugs that have become obsolete or have safer, more effective alternatives might be removed.
9.
The NLEM is crucial for public health programs like Ayushman Bharat. By ensuring the availability of essential medicines, it supports the delivery of comprehensive healthcare services under such schemes, making them more effective and accessible to beneficiaries.
10.
When UPSC asks about the NLEM, they are testing your understanding of its role in public health, its impact on drug pricing and affordability, and its connection to government policies. Examiners look for your ability to link the NLEM to broader issues like healthcare access, the pharmaceutical industry, and the government's commitment to universal health coverage. They might ask how it helps control 'financial toxicity' – a term used in the context of expensive cancer treatments like Keytruda.
11.
A common mistake students make is to think the NLEM is just a simple list of drugs. They fail to grasp its strategic importance as a policy instrument for price control, generic promotion, and ensuring equitable access to healthcare. They also often miss the dynamic nature of the list and its periodic revisions.
12.
The NLEM is often linked to the Drug Price Control Order (DPCO), which empowers the NPPA to fix or revise the ceiling prices of essential medicines. The NLEM provides the basis for which drugs fall under this price control mechanism.
13.
The WHO's Model List of Essential Medicines serves as a global benchmark. India's NLEM is aligned with this, but it's tailored to the specific disease burden, economic conditions, and healthcare infrastructure of India. This localization is key to its effectiveness.
14.
The NLEM plays a role in rational drug use. By highlighting essential medicines, it encourages healthcare providers to prescribe them over less essential or more expensive alternatives, promoting evidence-based medicine and reducing unnecessary expenditure.
15.
The inclusion of specific drugs on the NLEM can significantly impact the market for those drugs. Manufacturers may be incentivized to produce generic versions or ensure stable supply chains if their products are listed, as it guarantees a certain level of demand, particularly from government procurement.
Does not directly mandate price controls but influences procurement and policy.
Policy Tool
Guides government procurement, pricing, and public health programs (e.g., Ayushman Bharat).
Serves as a reference for national policy formulation.
Recent Updates
NLEM 2022 included COVID-19 drugs, certain cancer drugs.
WHO list updated periodically to reflect new scientific evidence and health priorities.
•Ensures accessibility: It guarantees that basic healthcare needs are met by making crucial drugs available in adequate quantities and at affordable prices.
•Guides public health: It serves as a roadmap for government procurement, pricing, and policy formulation, focusing resources on what matters most for public health.
•Promotes rational use: By focusing on a defined list, it encourages the use of proven, effective medicines and discourages the proliferation of unnecessary or costly alternatives.
3. How does the National List of Essential Medicines (NLEM) influence drug pricing in India, and what is the role of the NPPA?
Drugs listed in the NLEM are subject to price controls under the Drug Price Control Order (DPCO). The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for these essential medicines, ensuring they remain affordable.
•Price Ceiling Mechanism: The NPPA fixes the maximum price for scheduled formulations (drugs on the NLEM) based on cost-plus or market-based methods.
•DPCO 2013: This order, implemented under the Essential Commodities Act, empowers the NPPA to regulate prices of essential medicines.
•Impact on Affordability: By capping prices, the NLEM and NPPA directly address the affordability challenge, making critical treatments accessible to a larger population.
•Monitoring and Enforcement: NPPA monitors prices and takes action against manufacturers who violate the price regulations.
Exam Tip
Remember that NLEM drugs are 'scheduled formulations' under DPCO, and NPPA is the regulatory body. The key is the direct link between NLEM inclusion and price control by NPPA.
4. What are the biggest practical challenges in ensuring the availability of National List of Essential Medicines (NLEM) drugs across India?
The biggest challenge is ensuring consistent availability, especially in remote and rural areas, due to issues with supply chain management, distribution, and sometimes, manufacturers prioritizing more profitable non-NLEM drugs.
•Supply Chain Gaps: Inefficient logistics, storage, and transportation can lead to stockouts, particularly for temperature-sensitive medicines.
•Distribution Network Issues: Reaching remote and underserved areas with a consistent supply remains a significant hurdle.
•Manufacturer Incentives: While NLEM drugs are price-controlled, manufacturers might focus production on higher-margin, non-NLEM drugs if not adequately incentivized or mandated.
•Monitoring and Accountability: Effective real-time tracking of stock levels and demand across all public health facilities is complex.
•Procurement Delays: Bureaucratic processes in government procurement can delay the replenishment of essential medicines.
5. What is the one-line distinction between India's National List of Essential Medicines (NLEM) and the WHO's Model List of Essential Medicines?
India's NLEM is a country-specific list tailored to its population's health needs, disease burden, and healthcare system, while the WHO's Model List is a global template providing guidance for countries to adapt.
Exam Tip
NLEM = India-specific, adapted to local context. WHO Model List = Global template, for countries to adapt. India's first NLEM (1996) was based on the WHO list.
6. What is the strongest argument critics make against the National List of Essential Medicines (NLEM), and how would you respond?
Critics argue that price controls on NLEM drugs stifle innovation and reduce the availability of newer, potentially better treatments. The response is that NLEM prioritizes basic, proven needs, and innovation can be fostered through other mechanisms without compromising essential access.
•Critic's Argument: Price controls disincentivize R&D for essential medicines, leading to fewer new drugs and potential shortages of advanced treatments.
•Government Response (Perspective 1): NLEM focuses on established, cost-effective treatments crucial for public health. Innovation is encouraged for non-essential or advanced therapies.
•Government Response (Perspective 2): The list is dynamic (updated 2022) and includes newer drugs where public health impact and affordability are balanced, showing flexibility.
•Policy Balance: The goal is to balance affordability for essential needs with incentives for pharmaceutical innovation in other areas.
4.
The NLEM guides the government's price control mechanisms. Drugs listed in the NLEM are subject to price ceilings set by the National Pharmaceutical Pricing Authority (NPPA). This is a critical tool to ensure that essential medicines remain affordable for the common person, as seen with the ongoing debates around drug pricing.
5.
The NLEM is not just a list; it's a policy tool. It influences government procurement decisions, helping public health facilities stock essential medicines. It also guides state governments in formulating their own lists and procurement strategies, ensuring a more coordinated approach to drug availability across the country.
6.
The NLEM is divided into categories based on therapeutic areas, such as cardiovascular drugs, anti-infectives, and pain management. This categorization helps in organizing the list and ensures that a wide range of health conditions are covered.
7.
A major challenge is ensuring the availability of NLEM drugs. Inclusion on the list doesn't automatically guarantee supply. The government needs robust supply chain management and monitoring mechanisms to ensure that these medicines are actually available in public health facilities and pharmacies, especially in remote areas.
8.
The 2022 NLEM revision saw the inclusion of new drugs and the exclusion of others. For instance, it included drugs for conditions like COVID-19 and certain cancers, reflecting evolving health priorities. Conversely, drugs that have become obsolete or have safer, more effective alternatives might be removed.
9.
The NLEM is crucial for public health programs like Ayushman Bharat. By ensuring the availability of essential medicines, it supports the delivery of comprehensive healthcare services under such schemes, making them more effective and accessible to beneficiaries.
10.
When UPSC asks about the NLEM, they are testing your understanding of its role in public health, its impact on drug pricing and affordability, and its connection to government policies. Examiners look for your ability to link the NLEM to broader issues like healthcare access, the pharmaceutical industry, and the government's commitment to universal health coverage. They might ask how it helps control 'financial toxicity' – a term used in the context of expensive cancer treatments like Keytruda.
11.
A common mistake students make is to think the NLEM is just a simple list of drugs. They fail to grasp its strategic importance as a policy instrument for price control, generic promotion, and ensuring equitable access to healthcare. They also often miss the dynamic nature of the list and its periodic revisions.
12.
The NLEM is often linked to the Drug Price Control Order (DPCO), which empowers the NPPA to fix or revise the ceiling prices of essential medicines. The NLEM provides the basis for which drugs fall under this price control mechanism.
13.
The WHO's Model List of Essential Medicines serves as a global benchmark. India's NLEM is aligned with this, but it's tailored to the specific disease burden, economic conditions, and healthcare infrastructure of India. This localization is key to its effectiveness.
14.
The NLEM plays a role in rational drug use. By highlighting essential medicines, it encourages healthcare providers to prescribe them over less essential or more expensive alternatives, promoting evidence-based medicine and reducing unnecessary expenditure.
15.
The inclusion of specific drugs on the NLEM can significantly impact the market for those drugs. Manufacturers may be incentivized to produce generic versions or ensure stable supply chains if their products are listed, as it guarantees a certain level of demand, particularly from government procurement.
Does not directly mandate price controls but influences procurement and policy.
Policy Tool
Guides government procurement, pricing, and public health programs (e.g., Ayushman Bharat).
Serves as a reference for national policy formulation.
Recent Updates
NLEM 2022 included COVID-19 drugs, certain cancer drugs.
WHO list updated periodically to reflect new scientific evidence and health priorities.
•Ensures accessibility: It guarantees that basic healthcare needs are met by making crucial drugs available in adequate quantities and at affordable prices.
•Guides public health: It serves as a roadmap for government procurement, pricing, and policy formulation, focusing resources on what matters most for public health.
•Promotes rational use: By focusing on a defined list, it encourages the use of proven, effective medicines and discourages the proliferation of unnecessary or costly alternatives.
3. How does the National List of Essential Medicines (NLEM) influence drug pricing in India, and what is the role of the NPPA?
Drugs listed in the NLEM are subject to price controls under the Drug Price Control Order (DPCO). The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for these essential medicines, ensuring they remain affordable.
•Price Ceiling Mechanism: The NPPA fixes the maximum price for scheduled formulations (drugs on the NLEM) based on cost-plus or market-based methods.
•DPCO 2013: This order, implemented under the Essential Commodities Act, empowers the NPPA to regulate prices of essential medicines.
•Impact on Affordability: By capping prices, the NLEM and NPPA directly address the affordability challenge, making critical treatments accessible to a larger population.
•Monitoring and Enforcement: NPPA monitors prices and takes action against manufacturers who violate the price regulations.
Exam Tip
Remember that NLEM drugs are 'scheduled formulations' under DPCO, and NPPA is the regulatory body. The key is the direct link between NLEM inclusion and price control by NPPA.
4. What are the biggest practical challenges in ensuring the availability of National List of Essential Medicines (NLEM) drugs across India?
The biggest challenge is ensuring consistent availability, especially in remote and rural areas, due to issues with supply chain management, distribution, and sometimes, manufacturers prioritizing more profitable non-NLEM drugs.
•Supply Chain Gaps: Inefficient logistics, storage, and transportation can lead to stockouts, particularly for temperature-sensitive medicines.
•Distribution Network Issues: Reaching remote and underserved areas with a consistent supply remains a significant hurdle.
•Manufacturer Incentives: While NLEM drugs are price-controlled, manufacturers might focus production on higher-margin, non-NLEM drugs if not adequately incentivized or mandated.
•Monitoring and Accountability: Effective real-time tracking of stock levels and demand across all public health facilities is complex.
•Procurement Delays: Bureaucratic processes in government procurement can delay the replenishment of essential medicines.
5. What is the one-line distinction between India's National List of Essential Medicines (NLEM) and the WHO's Model List of Essential Medicines?
India's NLEM is a country-specific list tailored to its population's health needs, disease burden, and healthcare system, while the WHO's Model List is a global template providing guidance for countries to adapt.
Exam Tip
NLEM = India-specific, adapted to local context. WHO Model List = Global template, for countries to adapt. India's first NLEM (1996) was based on the WHO list.
6. What is the strongest argument critics make against the National List of Essential Medicines (NLEM), and how would you respond?
Critics argue that price controls on NLEM drugs stifle innovation and reduce the availability of newer, potentially better treatments. The response is that NLEM prioritizes basic, proven needs, and innovation can be fostered through other mechanisms without compromising essential access.
•Critic's Argument: Price controls disincentivize R&D for essential medicines, leading to fewer new drugs and potential shortages of advanced treatments.
•Government Response (Perspective 1): NLEM focuses on established, cost-effective treatments crucial for public health. Innovation is encouraged for non-essential or advanced therapies.
•Government Response (Perspective 2): The list is dynamic (updated 2022) and includes newer drugs where public health impact and affordability are balanced, showing flexibility.
•Policy Balance: The goal is to balance affordability for essential needs with incentives for pharmaceutical innovation in other areas.
